Boosted atazanavir approved in Europe as first-line therapy

HIV Treat Bull - 2008 July-August;9(7/8):

On 24th June 2008, the European Commission granted marketing authorisation for atazanavir boosted by ritonavir (300mg/100mg once daily), in combination with other antiretrovirals, as a first-line treatment HIV-1 infected adults. [1]

Previously, atazanavir/r was only recommended in treatment-experienced patients.

This decision was based on results from the non-inferiority CASTLE study which randomised almost 900 naïve patients to either once-daily atazanavir/r or twice-daily lopinavir/r with background tenofovir+FTC. Results were first presented at the Retrovirus conference in February and were reported in the March April issue of HTB. [2]

Efficacy was similar in both study arms; 78% vs 76% patients in the atazanavir/r and lopinavir/r arms respectively achieving viral load <50 copies/mL at week 48.

Safety events in the study were consistent with prior experience, and patients taking atazanavir/r experienced lower rates of Grade 2-4 adverse events such as diarrhoea (2%) and nausea (4%) than those taking lopinavir/r (11% and 8% respectively). Additionally, the atazanaivr/r arm was associated with significantly lower increases from baseline compared to the lopinavir/r arm in total cholesterol, triglycerides and non-HDL cholesterol at 48 weeks (all p<0.0001).

As with previous observation, 34% of the patients in the atazanaivr/r arm and less than 1% of patients in the twice-daily lopinavir/r arm experienced elevations in total bilirubin (hyperbilirubinaemia) greater than 2.5 times the upper limit of normal. This elevation was not associated with liver dysfunction as the rates of Grade 3-4 liver enzyme elevations were similar between treatment groups (2% in once-daily atazanaivr/r arm vs 1% in the twice-daily lopinavir/r arm).

Atazanavir 300mg boosted with 100mg ritonavir is now available in the UK for use in naïve patients.

comment

Many UK clinics were already using atazanavir/r as first line therapy as a once-daily PI option to efavirenz, and improved tolerability due to only requring 100mg dose of boosting ritonavir.

Atazanavir/r is now recommended as an alternative to efavirenz in the new BHIVA treatment guidelines (July 2008).

References:
1. Bristol-Myers Squibb press release. ‘European commission approves boosted Reyataz ’ 24 June 2008.
2. Atazanavir/r vs lopinavir/r in treatment-naïve patients: 48 week results. HTB March/April 2008. http://www.i-base.info/htb/v9/htb9-3-4/Atazanavir.html

2008-07-10
IB080907-09

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.